CCL

Összesen 6 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM038593
Első szerző:Cervera, Ricard
Cím:Antiphospholipid syndrome : clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients / Ricard Cervera, Jean-Charles Piette, Josep Font, Munther A. Khamashta, Yehuda Shoenfeld, Maria Teresa Camps, Soren Jacobsen, Gabriella Lakos, Angela Tincani, Irene Kontopoulou-Griva, Mauro Galeazzi, Pier Luigi Meroni, Ronald H. W. M. Derksen, Philip G. de Groot, Erika Gromnica-Ihle, Marta Baleva, Marta Mosca, Stefano Bombardieri, Frédéric Houssiau, Jean-Christophe Gris, Isabelle Quéré, Eric Hachulla, Carlos Vasconcelos, Beate Roch, Antonio Fernández-Nebro, Marie-Claire Boffa, Graham R. V. Hughes, Miguel Ingelmo, Euro-Phospholipid Project Group
Dátum:2002
ISSN:0004-3591
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Arthritis And Rheumatism 46 : 4 (2002), p. 1019-1027. -
További szerzők:Piette, Jean-Charles Font, Josep Khamashta, Munther A. Shoenfeld, Yehuda Camps, Maria Teresa Jacobsen, Soren Lakos Gabriella (1963-) (laboratóriumi szakorvos, transzfúziológus, immunológus) Tincani, Angela Kontopoulou-Griva, Irene Galeazzi, Mauro Meroni, Pier Luigi Derksen, Ronald H. W. M. de Groot, Philip G. Gromnica-Ihle, Erika Baleva, Marta Mosca, Marta Bombardieri, Stefano Houssiau, Frédéric Gris, Jean-Christophe Quéré, Isabelle Hachulla, Eric Vasconcelos, Carlos Roch, Beate Fernández-Nebro, Antonio Boffa, Marie-Claire Hughes, Graham R. V. Ingelmo, Miguel Soltész Pál (1961-) (belgyógyász, kardiológus) Zeher Margit (1957-2018) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Kiss Emese (1960-) (belgyógyász, immunológus) Euro-Phospholipid Project Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM002148
Első szerző:Kerekes György (belgyógyász, kardiológus, angiológus)
Cím:Endothelial dysfunction and atherosclerosis in rheumatoid arthritis : a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity / Kerekes György, Szekanecz Zoltán, Dér Henrietta, Sándor Zsuzsa, Lakos Gabriella, Muszbek László, Csípő István, Sipka Sándor, Seres Ildikó, Paragh György, Kappelmayer János, Szomják Edit, Veres Katalin, Szegedi Gyula, Shoenfeld Yehuda, Soltész Pál
Dátum:2008
Megjegyzések:Cardiovascular disease is a leading cause of mortality in rheumatoid arthritis (RA). Endothelial dysfunction often precedes manifest atherosclerosis. We assessed endothelial dysfunction and atherosclerosis in RA in context with laboratory markers. METHODS: Fifty-two patients with RA and 40 matched healthy controls were studied. We assessed common carotid intima-media thickness (ccIMT) and flow- (FMD) and nitroglycerine-mediated vasodilation (NMD). We also assayed numerous immunological and metabolic laboratory markers. RESULTS: FMD was significantly lower in RA (5.32% +/- 4.66%) compared to controls (8.30% +/- 3.96%) (p = 0.001). NMD was preserved in RA. ccIMT was significantly greater in patients with RA (0.63 +/- 0.14 mm) versus controls (0.54 +/- 0.15 mm) (p = 0.012). In patients with RA, ccIMT correlated with FMD% (R = -0.318, p = 0.022), age (R = 0.831, p < 0.001), and anti-dsDNA levels (R = 0.463, p = 0.006). FMD% correlated with serum interferon-gamma (IFN-gamma) levels (R = 0.516, p = 0.014). NMD% correlated inversely with the percentage of Th0 lymphocytes (R = -0.636, p = 0.006), serum immune complex (R = -0.692, p < 0.001), and IgM levels (R = -0.606, p = 0.003). Patients with RA were divided as "low" (< 0.65 mm) versus "high" (> 0.65 mm) ccIMT groups, and into "normal" (> 5%) versus "impaired" (< 5%) FMD% subsets. Low and high ccIMT groups differed significantly in age and serum interleukin 1 (IL-1) and anti-dsDNA levels. RA patients with normal versus impaired FMD% differed significantly in age, disease duration, and serum IFN-gamma levels. Lipoprotein(a) [Lp(a)] also correlated with rheumatoid factor (RF) and C-reactive protein (CRP); homocysteine (HCy) correlated with CRP and correlated inversely with folate and vitamin B12 production. Paraoxonase-1 (PON-1) activity correlated with serum tumor necrosis factor-alpha(TNF-alpha) and IL-6 levels. CONCLUSION: This was a well characterized RA population, where FMD and ccIMT were impaired, indicating early endothelial dysfunction and accelerated atherosclerosis, respectively. RA-related autoimmune-inflammatory mechanisms and metabolic factors including anti-CCP, RF, CRP, circulating immune complexes, IgM, TNF-alpha, IL-6, Th0/Th1 ratio, HCy, folate, vitamin B12, and PON-1 may all be involved in the development of vascular disease in RA. Although ccIMT and FMD, as well as some laboratory factors, have been assessed by other investigators in RA-associated atherosclerosis, our results regarding the possible involvement of anti-CCP, anti-dsDNA, Lp(a), some cytokines, and PON-1 activity are novel. Early determination of FMD% and ccIMT may be useful to assess RA patients with high cardiovascular risk.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:The Journal of Rheumatology. - 35 : 3 (2008), p. 398-406. -
További szerzők:Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Dér Henrietta (1977-) (orvos) Sándor Zsuzsa (1980-) (pathológus) Lakos Gabriella (1963-) (laboratóriumi szakorvos, transzfúziológus, immunológus) Muszbek László (1942-) (haematológus, kutató orvos) Csípő István (1953-) (vegyész) Sipka Sándor (1945-) (laboratóriumi szakorvos) Seres Ildikó (1954-) (biokémikus) Paragh György (1953-) (belgyógyász) Kappelmayer János (1960-) (laboratóriumi szakorvos) Szomják Edit (1961-) (belgyógyász) Veres Katalin (1971-) (orvos) Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Shoenfeld, Yehuda Soltész Pál (1961-) (belgyógyász, kardiológus)
Internet cím:elektronikus változat
Borító:

3.

001-es BibID:BIBFORM001209
Első szerző:Tarr Tünde (belgyógyász, allergológus és klinikai immunológus)
Cím:Primary antiphospholipid syndrome as the forerunner of systemic lupus erythematosus / Tarr T., Lakos G., Bhattoa H. P., Szegedi G., Shoenfeld Y., Kiss E.
Dátum:2007
Megjegyzések:The objective of this study was to analyse whether primary antiphospholipid syndrome (PAPS) may precede and modify the characteristics of systemic lupus erythematosus (SLE). Out of the total 362 SLE patients in our service, 223 patients had antiphospholipid antibodies (aPL), of whom 110 met the criteria of antiphospholipid syndrome. In 26 cases (7.2%) PAPS appeared 5.5 years before the onset of lupus (PAPS+SLE Group). Their clinical findings were compared to lupus patients without (SLE only Group, n=26) and with secondary APS (SLE+SAPS Group, n=26). The prevalence of deep venous thrombosis, stroke/TIA, recurrent fetal loss, coronary heart disease and myocardial infarction was significantly higher in PAPS+SLE Group as compared to SLE only Group. The difference in prevalence of fetal loss (P=0.014) between PAPS+SLE and SLE+SAPS Groups was also recorded. On comparison to PAPS+SLE Group, patients without APS (SLE only Group) were younger at onset of lupus, with more frequent flares and a higher prevalence of WHO type III/IV nephritis (P=0.007), requiring higher doses of cyclophosphamide and corticosteroids. Lupus started in the form of PAPS in 7.2% of our SLE patients, who presented with more thrombotic and less inflammatory complications than in SLE patients without a prior or with a following secondary APS. Considering the long latency between the two diseases, PAPS may be a forerunner of lupus, but it may also coexist with SLE as an independent autoimmune disorder
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
association
PAPS
SLE
Association
phospholipid antibody
adolescent
adult
antiphospholipid syndrome
article
deep vein thrombosis
female
fetus wastage
heart infarction
human
ischemic heart disease
major clinical study
male
nephritis
priority journal
recurrent disease
school child
stroke
systemic lupus erythematosus
transient ischemic attack
Adolescent
Adult
Antiphospholipid Syndrome
Child
Female
Humans
Lupus Erythematosus, Systemic
Male
Middle Aged
Megjelenés:Lupus 16 : 5 (2007), p. 324-328. -
További szerzők:Lakos Gabriella (1963-) (laboratóriumi szakorvos, transzfúziológus, immunológus) Bhattoa Harjit Pal (1973-) (laboratóriumi szakorvos) Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Shoenfeld, Yehuda Kiss Emese (1960-) (belgyógyász, immunológus)
Internet cím:elektronikus változat
DOI
Borító:

4.

001-es BibID:BIBFORM001208
035-os BibID:PMID:17283584
Első szerző:Tarr Tünde (belgyógyász, allergológus és klinikai immunológus)
Cím:Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients / T. Tarr, G. Lakos, H. P. Bhattoa, Y. Shoenfeld, Gy. Szegedi, E. Kiss
Dátum:2007
Megjegyzések:The objective of this study was to characterize risk factors for thrombotic events in lupus patients. A total of 272 lupus patients were followed up for five years during which the presence of aPL antibodies [anticardiolipin (aCL), anti-beta2-glycoprotein I (abeta2GPI) and lupus anticoagulant (LAC)] were determined, and all thrombotic incidents and antithrombotic therapy-related data were collected. At baseline, three groups were constituted, an aPL- group with 107 aPL negative patients, an aPL- group with 81 aPL positive patients without clinical thrombosis and a secondary antiphospholipid syndrome (APS) group with 84 aPL- patients who met the Sapporo criteria. LAC was more common in the APS than the aPL- group (32.1% versus 9.9%, P < 0.001). The prevalence of clinical thrombotic events was significantly higher when all three types of aPL were present compared to only aCL positive cases. During follow up, aPL appeared in 7.5% of the aPL- group, and 2.8% of this group had thrombotic complications. In the aPL- group, thrombotic events reoccurred in 1.9% of those receiving antithrombotic prophylaxis and 6.9% of those without primary prophylaxis. Despite anticoagulant therapy, thrombotic events reoccurred in 8.3% of the APS group. These findings indicate that LAC, constant and cumulative presence of aPL and previous thrombosis are positive predictors for the development of thrombotic complication in lupus patients.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
SLE
antiphospholipid antibodies
antiphospholipid syndrome
primary prophylaxis
thrombosis
Primary prophylaxis
acetylsalicylic acid
beta2 glycoprotein 1 antibody
cardiolipin antibody
clopidogrel
coumarin
fibrinolytic agent
lupus anticoagulant
phospholipid antibody
adult
antiphospholipid syndrome
article
controlled study
disease duration
female
follow up
heart infarction
human
major clinical study
male
prevalence
priority journal
prophylaxis
risk assessment
risk factor
stroke
systemic lupus erythematosus
thrombocytopenia
thrombosis
Adult
Antibodies, Anticardiolipin
Antibodies, Antiphospholipid
Antibody Specificity
Anticoagulants
Antiphospholipid Syndrome
Autoantigens
beta 2-Glycoprotein I
Cerebrovascular Accident
Female
Fibrinolytic Agents
Follow-Up Studies
Humans
Lupus Coagulation Inhibitor
Lupus Erythematosus, Systemic
Male
Middle Aged
Platelet Aggregation Inhibitors
Risk Factors
Thrombophilia
Thrombosis
egyetemen (Magyarországon) készült közlemény
Megjelenés:Lupus 16 : 1 (2007), p. 39-45. -
További szerzők:Lakos Gabriella (1963-) (laboratóriumi szakorvos, transzfúziológus, immunológus) Bhattoa Harjit Pal (1973-) (laboratóriumi szakorvos) Shoenfeld, Yehuda Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Kiss Emese (1960-) (belgyógyász, immunológus)
Internet cím:elektronikus változat
DOI
Szerző által megadott URL
Borító:

5.

001-es BibID:BIBFORM001205
035-os BibID:PMID:17916982
Első szerző:Tarr Tünde (belgyógyász, allergológus és klinikai immunológus)
Cím:Clinical thrombotic manifestations in SLE patients with and without antiphospholipid antibodies : a 5-year follow-up / Tünde Tarr, Gabriella Lakos, Harjit Pal Bhattoa, Pál Soltész, Yehuda Shoenfeld, Gyula Szegedi, Emese Kiss
Dátum:2007
Megjegyzések:Objective: To analyze the association of antiphospholipid antibodies (aPL) with the development of clinical thrombotic manifestations and to characterize the efficacy of anti-thrombotic therapies used. Methods: 272 systemic lupus erythematosus (SLE) patients participated in the study. Patient files and a cumulative database were used to collect patients' medical histories. Anti-cardiolipin (aCL), anti-beta2-glycoprotein I (a??2GPI) antibodies, and lupus anticoagulant (LAC) were measured according to international recommendations. New thrombotic events were registered during follow-up. Results: The patients were prospectively studied for 5 years, of whom 107 were aPL negative (aPL- group). Criteria for antiphospholipid syndrome (APS) were fulfilled by 84 of 165 aPL-positive patients (APS+ group) indicating that SLE patients with aPL have around 50% risk to develop thrombotic complications. The aPL+ group (n?ë♯n81) consisted of aPL+ but APS- patients. LAC was the most common aPL (n?ë♯n27, 32.1%) in patients with APS. The cumulative presence of aPL further increased the prevalence of thrombotic events. During the follow-up period, aPL developed in 8 of 107 patients (7.5%) from the aPL- group, of whom 3 (2.8%) presented with thrombotic complications. Other types of aPL developed in 7 of 165 (4.2%) aPL+ patients within 5 years. New thrombotic events occurred in 3.7% of aPL+ (n?ë♯n3) and 8.3% (n?ë♯n7) of the APS group. During follow-up, 52 of 81 aPL+ patients received primary prophylaxis, and 1 (1.9%) had transient ischemic attack (TIA). In the non-treatment group, 2 (6.9%) had stroke. Seventy-nine of 84 of the APS patients received secondary prophylaxis, and myocardial infarction occurred in 2 patients (on cumarine therapy maintaining an international normalized ratio around 2.5-3.0), and 5 suffered a stroke/TIA (1 on aspirin and 4 on aspirin+cumarine). Conclusion: The findings emphasize the importance of determining both aCL and a??2GPI antibodies and LAC in SLE patients and the need for adequate anticoagulant therapy. ?? Humana Press Inc. 2007.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
SLE
antiphospholipid antibodies
thrombotic manifestation
APS
Follow-up
LAC
Primary prophylaxis
acetylsalicylic acid
antithrombocytic agent
beta2 glycoprotein 1 antibody
cardiolipin antibody
coumarin
lupus anticoagulant
phospholipid antibody
adult
antiphospholipid syndrome
article
cerebrovascular accident
cohort analysis
controlled study
data base
deep vein thrombosis
disease association
disease course
drug efficacy
female
follow uphigh risk population
history of medicine
human
international normalized ratio
lung embolism
major clinical study
male
medical record
prevalence
prophylaxis
prospective study
stroke
systemic lupus erythematosus
thrombosis
transient ischemic attack
Adult
Antibodies, Antiphospholipid
Antibody Specificity
Anticoagulants
Antiphospholipid Syndrome
Aspirin
Cohort Studies
Female
Follow-Up Studies
Humans
Lupus Erythematosus, Systemic
Male
Middle Aged
Thrombosis
Time Factors
egyetemen (Magyarországon) készült közlemény
Megjelenés:Clinical Review of Allergy Immunology 32 : 2 (2007), p. 131-137. -
További szerzők:Lakos Gabriella (1963-) (laboratóriumi szakorvos, transzfúziológus, immunológus) Bhattoa Harjit Pal (1973-) (laboratóriumi szakorvos) Soltész Pál (1961-) (belgyógyász, kardiológus) Shoenfeld, Yehuda Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Kiss Emese (1960-) (belgyógyász, immunológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Szerző által megadott URL
Borító:

6.

001-es BibID:BIBFORM007151
Első szerző:Veres Katalin (orvos)
Cím:Antiphospholipid antibodies in acute coronary syndrome / Veres, K., Lakos, G., Kerenyi, A., Szekanecz, Z., Szegedi, G., Shoenfeld, Y., Soltesz, P.
Dátum:2004
ISSN:0961-2033 (Print)
Megjegyzések:Antiphospholipid (aPL) antibodies entailing anticardiolipin (aCL) and anti-beta2 glycoprotein I (anti-beta2GPI) antibodies may be involved in a number of vascular diseases including coronary artery diseases (CAD) or stroke. Here we assessed the presence of aPL antibodies in acute coronary syndrome (ACS). The frequency of anti-beta2GPI antibodies was significantly higher (14.4%) in ACS in comparison to control healthy subjects (2%). In addition, serum concentrations of anti-beta2GPI antibodies were also increased in ACS. Anti-beta2GPI antibodies of the IgA isotype might be the most relevant for the onset and outcome of ACS. Regarding subclasses of ACS, anti-beta2GPI IgA antibodies were elevated in unstable angina (UA) and myocardial infarction with ST elevation (STEMI), but not in myocardial infarction without ST elevation (NSTEMI). The involvement of anti-beta2GPI antibodies in ACS was more pronounced in men than women, and in younger rather than older patients. Finally, anti-beta2GPI antibodies in ACS were associated with previous stroke, but not with hypertension or previous myocardial infarction. Thus, anti-beta2GPI antibodies may be involved in the thrombotic events underlying ACS.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Adult
Aged
Aged, 80 and over
Antibodies, Anticardiolipin
Antibodies, Antiphospholipid
Enzyme-Linked Immunosorbent Assay
Female
Glycoproteins
Humans
Lupus Coagulation Inhibitor
Male
Middle Aged
Myocardial Infarction
Risk Factors
beta 2-Glycoprotein I
Megjelenés:Lupus. - 13 : 6 (2004), p. 423-427. -
További szerzők:Lakos Gabriella (1963-) (laboratóriumi szakorvos, transzfúziológus, immunológus) Kerényi Adrienne (1970-) (laboratóriumi szakorvos) Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Shoenfeld, Yehuda Soltész Pál (1961-) (belgyógyász, kardiológus)
Internet cím:elektronikus változat
elektronikus változat
DOI
Borító:
Rekordok letöltése1 
Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.